The PREVEND Study is a prospective, observational cohort study, focussed to assess the impact of elevated urinary albumin loss in non-diabetic subjects on future cardiovascular and renal disease. PREVEND is an acronym for Prevention of REnal and Vascular ENd-stage Disease. This study started with a population survey on the prevalence of micro-albuminuria and generation of a study cohort of the general population. The goal is to monitor this cohort for the long-term development of cardiac-, renal- and peripheral vascular end-stage disease. For that purpose the participants receive questionnaires on events and are seen every three/four years for a survey on cardiac-, renal- and peripheral vascular morbidity.

Overview

Acronym

PREVEND

Website

PREVEND Website

Investigators
Contacts
Start Year

1997

General Design

Study Design Cohort
Recruitment Target
  • Individuals
Number of Participants

8,592

Number of Participants with Biological Samples

8,592

Supplementary Information

Of the 85,421 subjects invited 40,856 responded (=48%) . We invited all consenting subjects with a morning urinary albumin concentration (UAC) of >10 mg/L (n=7,768) and an a-select sample of those with an UAC <10 mg/L (n=3,395) for further studies . Of these invitees 8,592 subjects completed the first screening, that was held in 1997/1998

Access

Yes
No
Not Applicable
Don't Know
Possible Access to Data

Possible Access to Biosamples

Other

Marker Paper

Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. J Am Soc Nephrol. 2000 Oct;11(10):1882-8

PUBMED 11004219

Study Timeline

Each colour in the timeline graph below represents a separate Study Population, while each segment in the graph represents a separate Data Collection Event. Clicking on a segment gives more detailed information on a Data Collection Event.

Population

PREVEND cohort

The Prevend cohort is enriched for the presence of an elevated urinary albumin excretion (UAE). The population is formed of Groningen inhabitants aged 28 to 75 years, who agreed to give a morning urine and to answer a short questionnaire. Of the 85,421 subjects invited to participate, 40,856 responded. The final sample is constisted of 8,592 consenting subjects with a morning urinary albumin concentration (UAC) of >10 mg/L and an a-select sample of those with an UAC <10 mg/L who completed the first screening. Pregnant women and participants with diabetes mellitus were excluded.

Sources of Recruitment

General Population
  • Volunteer enrolment

Selection Criteria

Age Minimum age 18, Maximum age 75
Country Netherlands
Ethnic Origin Caucasian

Sample Size

Number of Participants

8,592

Number of Participants with Biological Samples

8,592

Data Collection Events

NameDescriptionStartEnd
NC1

The subjects were seen for two visits at the...

19971998
Second screening

First follow-up of the participants. The same...

20012003
Third screening

Second follow-up of the participants. The same...

20032006
Fourth Screening

To be completed...

20092012
Loading...
Loading...

Variables classifications